Radius Health & Menarini Group provide elacestrant update

Radius Health, Inc. (“Radius” or the “Company”) and the Menarini Group today announced an update on the elacestrant Phase 3 EMERALD trial.

EMERALD Phase 3 Study
The target enrollment milestone has been reached in the Phase 3 EMERALD clinical trial of elacestrant. Elacestrant is an oral Selective Estrogen Receptor Degrader (SERD) that is being studied in postmenopausal women and men with ER+/HER2- advanced or metastatic breast cancer. The study reached its enrollment goal of 466 patients overall, including 220 (47%) with tumors harboring an ESR1 mutation as detected in circulating tumor DNA by the Guardant Health Guardant360 liquid biopsy test.

Patients will be followed until the required number of events to assess progression-free survival – the primary endpoint of the study – is reached at which time the primary analysis will be performed. It is anticipated that this analysis will take place in the second half of 2021.

An independent data monitoring committee (IDMC) has been continuously monitoring the safety and efficacy of patients enrolled in the EMERALD trial. After enrollment of 70% of planned patients, the committee formally reviewed results of a futility analysis. In completing their review, the IDMC recommended that the trial continues to advance in an unmodified manner.

“We are thrilled about the continued progress for the program. Elacestrant continues to be the most advanced oral SERD in Phase 3 development and given that, we aim on being first to deliver Phase 3 data in the class, and upon clinical success, a regulatory submission,” said Elcin Barker Ergun, Chief Executive Officer of the Menarini Group.

Commenting further, Barker Ergun added that “the Menarini/Radius partnership has been a tremendous success to date and the completion of patient enrollment in the EMERALD trial brings us one step closer to bringing an oral SERD to women and men with advanced breast cancer.”

Dr. Maureen Conlan, Oncology Therapeutic Area Head for Radius, commented “Completing the enrollment of the EMERALD trial, despite the challenges of the COVID-19 pandemic, has been a great achievement. I am grateful to our team as well as the study investigators and patients for their efforts to date in supporting and participating in this trial.”

In summarizing on recent progress, Dr. Charles Morris, Chief Medical Officer for Radius added “This is an exciting milestone for Radius and our partner, the Menarini Group, with regard to the elacestrant program. We look forward to seeing additional advancement of the program including activities related to various life cycle management opportunities for the compound.” PR NewsWire

Share this:

Related Post

Stay Updated on Medical Equipment and Devices industry.
Receive our Daily Newsletter.